Related Experiment Video
Updated: Oct 9, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Longitudinal Clinical Foundation Models Augmented with Genomics for Early Detection and Risk Stratification of
Abstract:
Hypertrophic and dilated cardiomyopathy (HCM and DCM) carry substantial morbidity and mortality, yet diagnosis may be delayed, particularly when presentation is nonspecific. Existing machine-learning approaches to cardiomyopathy phenotyping, genotype prediction, and risk stratification commonly rely on disease-specific, hand-engineered features drawn from echocardiography, cardiac MRI, ECG, or curated clinical variables. We evaluated whether a general-purpose clinical foundation model, CLMBR-T-base, pre-trained via next-clinical-event prediction with no cardiomyopathy-specific supervision, could produce linearly separable embeddings for all three case/control cohorts. Using EHR data from the Penn Medicine BioBank, we constructed cohorts for (1) prediction of a first recorded qualifying HCM/DCM diagnosis at 1-, 3-, and 6-month horizons, decomposed into eventual-versus-never-case and imminent-versus-eventual comparisons; (2) genetic carrier status prediction among diagnosed patients with completed gene panels; and (3) prediction of heart-failure hospitalization, and all-cause mortality as both binary and time-to-event outcomes. Linear probes fitted to frozen embeddings achieved AUROCs of 0.75-0.82 for onset prediction, 0.74-0.75 for genotype status, and Harrell's concordance of 0.65-0.80 for time-to-event outcomes. Decomposing the onset prediction task reveals that the model often misclassifies patients who were diagnosed later as positive, suggesting the patient journey embeddings encode disease state more reliably than care timing. These results suggest that a single, generically pretrained EHR embedding can support multiple clinically motivated prediction problems in CM without disease-specific feature engineering.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Pharmacogenomics: Identification of New Drug Targets
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...